Interleukin-32 (IL-32) is a pro-inflammatory cytokine conditionally produced by T cells, natural killer (NK) cells, monocytes, epithelial cells and keratinocytes, which has an important role in host resistance against infectious disease. Interestingly, elevated levels of IL-32 transcripts in fine needle aspirates of tumor tissue have also been correlated with objective clinical responses in cancer patients receiving immunotherapy. To evaluate the antitumor impact of IL-32 gene therapy, we treated BALB/c mice bearing established subcutaneous CMS4 sarcomas with intratumoral (i.t.) injections of syngenic dendritic cells (DCs) engineered to express human IL-32b complementary DNA (that is, DC.IL32). Although ectopic expression of IL-32b by DC resulted in only modest phenotypic changes in these antigen-presenting cells, DC.IL32 produced higher levels of IL-12p70 than control DC. DC.IL32 were more potent activators of type-1 T-cell responses in vitro and in vivo, with i.t. administration of DC.IL32 leading to the CD8 þ T-cell-dependent (but CD4 þ T-cell-and NK cell-independent) suppression of tumor growth. Effective DC.IL32-based therapy promoted infiltration of tumors by type-1 (that is, CXCR3 þ VLA-4 þ GrB þ ) CD8 þ T cells and CD11b þ CD11c þ host myeloid DC, but led to reductions in the prevalence of CD11b þ Gr1 þ myeloid-derived suppressor cells and CD31 þ blood vessels.
Introduction
Dendritic cells (DCs) are highly efficient, specialized antigen-presenting cells (APC) that have a pivotal role in the cross-priming of protective antitumor immunity. 1 We have previously shown that direct intratumoral (i.t.) delivery of DC may result in profound antitumor effects and durable CD8 þ T-cell-mediated immunity, particularly when these APC are conditioned or engineered to promote type-1 immunity. [2] [3] [4] In particular, we previously observed that i.t. injection of DC engineered to produce both interleukin (IL)-12p70 and IL-18 yielded acute, robust antitumor effects in the (H-2 d ) CMS4 sarcoma model that exceeded that observed for DC transduced with IL-12p70 complementary DNA (cDNA) or IL-18 cDNA alone. 4 Interestingly, the combination of IL-12 and IL-18 has been defined as a strong stimulus for production of the pro-inflammatory cytokine IL-32, also known as natural killer (NK) cell protein 4. [5] [6] [7] [8] IL-32 exists in multiple isoforms (that is, IL-32a, IL-32b, IL-32g, IL-32d and IL-32z) that appear structurally unique among the known cytokine families and are potent inducers of IL-1, IL-6, IL-8, tumor necrosis factor (TNF)-a and MIP-2/ CXCL2. 6, 7, 9 IL-32 activates the nuclear factor-kB, p38 mitogen-activated protein kinase and activating protein-1 signaling pathways, 6,10 important for DC maturation 11, 12 and the corollary cross-priming of inflammatory type-1 T-cell-mediated immunity. 13, 14 Such immune responses appear to be causally or casually (positively) associated with inflammatory/autoimmune disorders such as rheumatoid arthritis, ulcerative colitis, Crohn's disease, inflammatory bowel disease, atopic dermatitis and Wegener's granulomatosis. 8, [14] [15] [16] [17] However, IL-32 also appears important for the development and maintenance of protective type-1 immunity in the infectious disease setting; that is, human immunodeficiency virus-1, 10 herpes simplex virus and vesicular stomatitis virus, 18 human papillomavirus 19 and tuberculosis. 20 In the cancer setting, IL-32 (aka NK4) has been identified as a marker associated with patient clinical responsiveness to IL-2-based immunotherapy as determined by gene array profiles obtained from fine needle aspirates of melanoma lesions pre-versus post-treatment. 21 Despite the lack of a homologous murine IL-32 molecule, 6 human IL-32 (hIL-32) is bioactive in mice. Hence, the injection of hIL-32 into the knee joints of mice results in joint swelling, tissue infiltration by immune cells and tissue pathology 14 and provision of hIL-32b to mice leads to the expected increase in systemic levels of IL-1, TNF-a and IL-6 in these animals. 8 Given these preliminary data, we investigated the antitumor impact of delivering murine DC engineered to express hIL-32b (DC.IL32) into CMS4 sarcomas established in syngenic BALB/c mice.
Subjects and methods
Mice BALB/c (H-2 d ) mice (6-to 8-week-old, female) were purchased from the Jackson Laboratory (Bar Harbor, ME). All mice were maintained in micro-isolator cages within the pathogen-free, central animal facility at the University of Pittsburgh. All studies were performed under an IACUC-approved protocol and in accordance with the recommendations for the proper care and use of laboratory animals.
Tumor cell lines and culture The H-2 d CMS4 and MethA sarcoma cell lines have been previously described. 22 The murine Raw 264.7 macrophage cell line was purchased from the American Type Culture Collection (ATCC; Manassas, VA). All cell lines were cultured in RPMI 1640 supplemented with 10% heatinactivated fetal calf serum, 100 U ml -1 penicillin, 100 mg ml -1 streptomycin, 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate (designated as culture media; all reagents from Life Technologies, Grand Island, NY).
Recombinant Ad.hIL-32b construction cDNA encoding human hIL-32b protein was amplified by PCR from the plasmid pORF9-hIL-32b (Invivogen, San Diego, CA) using specific primers (forward: 5 0 -GCGGCA TGCGGACACCATGGCGTGCTTCCCGAAGGTCC TCTCTG-3 0 and reverse: 5 0 -GCGCCCGGGACCTCAT TTTGAGGATTGGGGTTCAG-3 0 ), and then subcloned into a SphI-XmaI restriction site in the pAdLox vector (Invitrogen, San Diego, CA). After sequence validation, recombinant adenovirus was generated by co-transfection of pAdLox.hIL-32b and helper virus DNA into the ecotropic adenoviral packaging cell line CRE8. [2] [3] [4] The harvested recombinant adenovirus hIL-32b (Ad.hIL-32b) was purified by cesium chloride densitygradient centrifugation and subsequent dialysis before storage in 3% threalose at À80 1C. Titers of viral particles were determined by optical densitometry. The mock (empty) adenoviral vector Ad.c5 (refs 2-4) was used as a negative control.
DC preparation and transduction with recombinant adenovirus
Bone marrow-derived DC were generated from BALB/c mice over 5 days in cultures containing rmIL-4 and rmGM-CSF (Peprotech, Rocky Hill, NJ) as previously described. [2] [3] [4] On day 7, CD11c þ DC were purified using specific magnetic-activated cell selection beads (Miltenyi Biotec, Auburn, CA) and transduced with control adenovirus (Ad.c5) or Ad.IL32b at a multiplicity of infection (MOI) of between 50 and 500, as indicated in individual experiments. Infected DC were harvested after 48 h and analyzed for their phenotype (using flow cytometry (FCM)) and function in vitro and in vivo as indicated in the text.
Antibodies
The following mAbs were purchased from BD Biosciences (San Diego, CA): anti-H-2K d mAb (SF1-1.1) fluorescein isothiocyanate (FITC), anti-I-A d mAb (39-10-8) FITC, anti-B220 (RA3-6B2) phycoerythrin (PE), anti-CD8a (53-6.7) PE, anti-mCD40 mAb (3/23) FITC, anti-mCD54 mAb (3E2) FITC, anti-mCD80 mAb (16-10A1) FITC, anti-mCD86 mAb (GL1) FITC, anti-mGr1 (RB6-8C5) FITC, and anti-mCD11b (M1/70) PE, anti-mCD11c (HL3) APC. Anti-mCD49d (VLA4; PS/2) APC was purchased from SouthernBiotech (Birmingham, AL). Anti-granzyme B (GrB; 16G6) Alexa Fluor 647 was purchased from eBioscience (San Diego, CA). The following reagents were purchased from BioLegend (San Diego, CA): anti-mCCR7 (4B12) Alexa488, anti-mCXCR3 (CXCR3-173) APC, purified anti-hIL-32abd (KU32-56) and biotin-labeled anti-hIL-32abgd (KU32-52). These latter two reagents were used to establish a hIL-32b enzyme-linked immunosorbent assay (ELISA) assay. Purified anti-mouse TNF-a (TN3-19.12) and biotinylated anti-mouse TNF-a (Poly5062) were used in ELISA assays. PE-labeled anti-mouse forkhead box protein 3 (Foxp3) mAb (NRRF30) and its staining kit were obtained from eBioscience.
Cytokine ELISAs
DC culture supernatants and cell lysates were harvested for analysis of cytokine levels using specific ELISA. In some experiments, as indicated, DCs were stimulated by co-culture with CD40L þ J558 cells (kindly provided by Dr Pawel Kalinski, University of Pittsburgh) at a ratio of 1:1 for 24 h, before harvest of supernatants for cytokine quantitation. hIL-32b ELISA was constructed using probes from BioLegend as described in the preceding section, with a lower limit of detection of 7.5 pg ml -1 . As there was no current commercial source for rhIL-32b, we used rIL-32a (ProSpec, Rehovot, Israel) to establish the standard curve in this ELISA. DC and/or T-cell culture supernatants were also evaluated using specific ELISAs for levels of secreted mIL-10 (BD Biosciences), mIL-12p70 (BD Biosciences), mIL-18 (R&D Systems, Minneapolis, MN), mTNF-a (BioLegend), mIFN-a (PBL InterferonSource, Piscataway, NJ) and mIFN-g (BD Biosciences).
Assessment IL-32b biologic activity hIL-32 bioactivity was evaluated by culturing cell-free supernatants harvested from DC.IL32 or control DC with murine Raw 264.7 cells (5 Â 10 4 cells per well) for 18 h at 37 1C and 5% CO 2 . Supernatants were then harvested from these cultures and analyzed for mTNF-a content using a specific ELISA (BioLegend).
Mixed lymphocyte reaction (MLR)
To evaluate the allostimulatory function of control versus engineered DC, MLRs were performed as previously described, with minor modification. 3 Control H-2 b DC (DC.null) or Ad-infected DC (DC.c5 or DC.IL32) were seeded (2 Â 10 4 cells per well) in round-bottom 96-well plates. CD8 þ magnetic-activated cell selection (Miltenyi Biotec) splenic T cells from wild-type BALB/c (H-2 d ) mice were labeled with 0.5 mM carboxyfluorescein succinimidyl ester (CFSE) (Sigma-Aldrich, St Louis, MO) for 15 min at room temperature, after which, T cells were washed three times with culture media and 2 Â 10 5 cells added to control wells or wells containing DC in a total volume of 200 ml culture media per well. In analyses of myeloid-derived suppressor cell (MDSC) and regulatory T cell (Treg) suppressor function, CD4 þ CD25 neg BALB/c splenocytes were isolated by magnetic-activated cell selection (Miltenyi Biotec), labeled with CFSE as noted directly above and (10 5 cells) cultured with 2 Â 10 4 H-2 b control DC.null cells in the absence or presence of MDSC or Treg at a suppressor cell-to-CD4 þ T-cell ratio of between 0.5:1 and 2:1, as indicated in text. After 72 h of culture, cells were harvested and analyzed by FCM for dilution of CFSE signal as an index of CD4 þ T-cell proliferation. Triplicate determinations were used in all instances, with data reported as the mean ± s.d. Cell-free supernatants were also analyzed for production of interferon (IFN)-g and IL-10 using commercial ELISAs (all BD Biosciences).
CMS4 therapy model
For therapeutic experiments, BALB/c mice were injected subcutaneously with 5 Â 10 5 CMS4 sarcoma cells in the right flank on day 0, with tumors allowed to establish for 7 days. On day 7 after tumor implantation, the mice were randomized into cohorts of five animals each (with each cohort exhibiting a mean tumor size of approximately 40 mm 2 ) and left untreated or treated by i.t. injection of 1-2.5 Â 10 6 control DC (DC.null or DC.c5) or DC.IL32 (10 6 ) in a total volume of 50 ml (in PBS) on days 7 and 14 post-tumor inoculation. Tumor size was assessed every 3 or 4 days and recorded in mm 2 by determining the product of the largest perpendicular diameters measured by vernier calipers. In some experiments, as indicated, in vivo antibody depletions (on days 6, 13 and 20 post-tumor inoculation) of CD4 þ T cells, CD8 þ T cells and asialo-GM1 þ NK cells were performed as previously described. 3 Evaluation of splenic CD8 þ T-cell responses against CMS4 tumors ex vivo Spleens were harvested 1 week after the second treatment (that is, day 21 after tumor inoculation), with 2 Â 10 6 splenocytes stimulated with 2 Â 10 5 irradiated (100 Gy) CMS4 cells for 5 days in the presence of low-dose (30 IU ml -1 ) rhIL-2 (Peprotech). Responder CD8 þ T cells were then isolated by specific magnetic-activated cell selection (Miltenyi Biotec), with CD8 þ T cells (2 Â 10 5 ) then co-cultured with 2 Â 10 4 CMS4 or control (H-2 d ) MethA sarcoma cells for 48 h at 37 1C and 5% CO 2 . Cell-free supernatants were then harvested and analyzed for IFN-g by ELISA (BD Biosciences). Data are reported as the mean ± s.d. of triplicate determinations.
Imaging of tumor tissues
Tumor samples were prepared and sectioned as previously reported. 23 For analysis of T-cell subsets, sections were first stained with purified rat anti-mouse CD8a or purified rat anti-mouse CD4 (both from BD-Pharmingen, San Diego, CA) mAbs for 1 h. After washing, sections were stained with Alexa Fluor 488-conjugated goat anti-rat secondary antibody (Jackson ImmunoResearch, West Grove, PA). To detect DCs in tumor tissue, tissue sections were stained with FITC-conjugated anti-mouse CD11c antibody (BD Biosciences). In some assays, as indicated, DC were first labeled with 0.5 mM CFSE before injection, with tissue sections then stained using a PE-conjugated anti-mouse CD11c antibody (BD Bioscience) in order to discriminate injected from endogenous DC populations in the tumor microenvironment (TME). For co-analysis of CD4 and Foxp3 expression, sections were washed and incubated with FITC-conjugated anti-mouse CD4 antibody and PE-conjugated anti-mouse Foxp3 antibody (eBioscience). For analysis of CD11b þ Gr1 þ MDSC, tissue sections were incubated with PE-conjugated rat anti-mouse CD11b and FITC-conjugated anti-mouse Gr1 (both from BD-Pharmingen). For analysis of CD31 and NG2 markers, the tissue sections were first incubated with rat anti-mouse CD31 and rabbit anti-mouse NG2 (both from Millipore, Bedford, MA) for 1 h at room temperature, then washed with 0.5% bovine serum albumin and stained with Alexa Fluor 488-conjugated goat anti-rat antibody and Cy3-conjugated goat anti-rabbit antibody (both from Invitrogen). To determine in situ cell death, the In situ Cell Death Detection Kit (Roche Diagnostics, Indianapolis, IN) was used. After staining with primary and secondary antibodies, the slides were washed and counterstained with 2 mg ml -1 Hoechst 33258 (Sigma-Aldrich) for 30 s. After washing, sections were then covered in Gelvatol (Monsanto, St Louis, MO) and a coverslip applied. Slide images were acquired using an Olympus 500 scanning confocal microscope (Olympus America, Center Valley, PA). The positively stained cells were quantified by analyzing the images at a final magnification of Â 20. Cell number and vascular area was analyzed using Metamorph Imaging software (Molecular Devices, Sunnyvale, CA).
Reverse transcriptase-PCR
Reverse transcriptase-PCR was performed as previously described 23 using the following primer pairs; TNF-a (forward) 5 0 -ATGAGCACAGAAAGCATG-3 0 , (reverse) 5 0 -GAAGACTCCTCCCAGGTA-3 0 (606-bp product); CCL2 (forward) 5 0 -CTGTGCTGACCCCAAGAAG G-3 0 , (reverse) 5 0 -TGCTTGAGGTGGTTGTGGAA-3 0 (191-bp product); CCL7 (forward) 5 0 -AATGCATCCAC ATGCTGCTA-3 0 , (reverse) 5 0 -CTTTGGAGTTGGG GTTTTCA-3 0 (204-bp product); CCL20 (forward)
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FCM analysis of tumor-infiltrating cells
Surgically harvested tumors were enzymatically digested and viable single-cell suspensions analyzed by FCM as previously described. 24 Statistical analysis Statistical differences between groups were evaluated by applying a two-tailed Student's t-test. All data are presented as the mean ± s.d. P-values o0.05 were considered to be statistically significant.
Results
Murine DC.IL32 produces bioactive hIL-32b protein Murine bone marrow-derived DC were generated in 5 day cultures supported by rmIL-4 and rmGM-CSF, then either left untreated or they were infected at various MOIs with Ad.hIL-32b (produced as described in Subjects and methods section) or control Ad.c5 for 48 h. As depicted in Figure 1 , DC.IL32 express the specific transgenic protein based on intracellular staining monitored by FCM (Figure 1a ), as well as, ELISA performed on DC.IL32 cell lysates and the cell-free supernatants harvested from these cultures ( Figure 1b) . Notably, the levels of ectopic IL-32 protein expressed in DC.IL32 were directly related to the MOI used for viral infection, and control DC (DC.null and DC.c5) populations were deficient in IL-32b expression (Figures 1a and b ). To determine if the DC.IL32-secreted cytokine was bioactive, we applied the harvested supernatants to the murine Raw 264.7 macrophage cell line, which has been reported to produce mTNF-a in response to hIL-32. 6 As shown in Figure 1c , supernatants harvested from DC.IL32 cells promoted elevated levels (versus control DC) of TNF-a production from Raw 264.7 cells at MOIsX100 (Po0.05 versus DC.null and DC.c5). On the basis of the data obtained in Figures 1b and c, we applied an 'optimal' MOI of 250 (for Ad.IL-32b infections) in generating DC.IL32 in all prospective experiments.
In vitro phenotype and functional analyses of DC.IL32 DC.IL32 and control DC were analyzed by FCM for expression of cell surface molecules associated with antigen-presentation (major histocompatibility complex (MHC) class I, MHC class II), T-cell co-stimulation (CD40, CD54, CD80 and CD86) and migration to secondary lymph nodes (CCR7). As shown in Figure 2a , DC.IL32 expressed higher levels of many of these markers when compared with DC.null or DC.c5; that is, MHC class I (mean fluorescence intensity (MFI) of 2575 versus 1570 and 1870, respectively), CD40 (MFI 185 versus 140 and 139, respectively), CD54 (MFI 1340 versus 974 and 1040, respectively), CD80 (MFI 1670 versus 1232 and 1240, respectively), CD86 (MFI 535 versus 303 and 309, respectively) and CCR7 (MFI 416 versus 319 and 323, respectively). MHC class II expression was not appreciably altered as a consequence of IL-32b cDNA gene insertion into DC (MFI 254 for DC.IL32 versus MFI 241 and 239 for DC.null and DC.c5, respectively). Consistent with our previous work, 4 infection of DC with control Ad.c5 had minimal impact on the immunostimulatory phenotype of these APC. To address whether Ad.IL-32b infection of DC altered their capacity to secrete type-1 polarizing cytokines, we stimulated DC.IL32 or control DC with CD40L þ J558 cells and analyzed the cell-free supernatant for cytokine levels by ELISA. As shown in Figure 2b , DC.IL32 produced significantly greater levels of IL-12p70, but not IL-18, when compared with DC.null or DC.c5 (Po0.01). Interestingly, despite the ability of DC.IL32 elaborated cytokine to promote Raw 264.7 production of TNF-a, DC.IL32 cells themselves failed to produce higher levels of TNF-a versus control DC in response to CD40 ligation (Figure 2b ).
DC.IL32 promote superior development of allo-reactive Tc1 cells in vitro
Given the observed upregulation of MHC class I (but not class II) and co-stimulatory molecules on, as well as IL-12p70 production by, DC.IL32, we hypothesized that these APC could promote superior type-1 CD8 þ T-cell (that is, Tc1) responses in vitro. This was analyzed in mixed leukocyte reaction (MLR) experiments, using DC.IL32 (or control DC) prepared from C57BL/6 (H-2 b ) mice as stimulators cells and CFSE-labeled splenic CD8 þ T cells isolated from BALB/c (H-2 d ) mice as responder cells. Although DC.IL32 failed to elicit differential proliferative responses from allogenic T cells when compared with control DC (Figures 3a and b) , these APC were stronger activators of alloreactive CD8 þ T cells producing IFN-g when compared with either DC.null or DC.c5 (Figure 3c ; Po0.01). In marked contrast, IL-10 production was reduced when comparing allogenic T cells stimulated with DC.IL32 versus control DC (Figure 3c, Po0.05) . IFN-g and IL-10 were produced solely by T cells and could not be detected in any DC stimulator population (data not shown). These data suggest that ectopic IL-32b contributes predominantly (type-1) differentiative, rather than proliferative, signals provided by DC.IL32 to responding CD8 þ T cells.
I.t. delivery of DC.IL32 prevents CSM4 tumor growth by promoting tumor-specific Tc1 responses in vivo
To evaluate the possible therapeutic benefits associated with IL-32b gene-modified DC, we treated BALB/c mice harboring day 7 established (subcutaneous) CMS4 sarcomas by i.t. injection with 1 Â 10 6 DC.IL32 or control DC on days 7 and 14 post-tumor inoculation. As shown in Figure 4a , all tumor-bearing mice treated with control DC exhibited progressively growing tumors, while animals treated using DC.IL32 displayed disease stabilization through day 19, after which, slow tumor growth was observed. Although all tumor-bearing animals treated i.t. with 10 6 DC.IL32 ultimately succumbed to their disease, they exhibited extended overall survival (Figure 4b ). However, if the i.t. dose of DC.IL32 were increased to 2.5 Â 10 6 cells per injection, 30% of treated animals exhibited complete tumor regression and long-term disease-free status (Figure 4b ). Antibody-based depletion of CD8 þ T cells, but not CD4 þ T cells or asialoGM1 þ NK cells ablated protection associated with DC.IL32based therapy in this model (Figure 4a ). The protective influence of therapy-induced Tc1 cells was further suggested by the ability of day 21 CD8 þ T cells isolated from the spleens or tumor-draining lymph nodes of DC.IL32 (but not control DC)-treated mice to differentially recognize CMS4 tumor cells versus unrelated (H-2 d ) MethA sarcoma cells in vitro (Figure 4c ; Po0.01 versus the DC.null or DC.c5 treatment groups).
Effective i.t. DC.IL32 therapy is associated with increased tumor infiltration by T cells, host CD11c þ DC and tumor/stromal cell apoptosis
As effective immunotherapy is believed to require increased tumor infiltration by (type-1) T cells and improved cross-priming by host APC, 25 we next evaluated whether DC.IL32-based therapy alters the prevalence of CD4 þ T cells, CD8 þ T cells and CD11c þ DC in the TME. CMS4 tumors were isolated from mice on day 21 post-tumor inoculation (that is, 1 week after the second i.t. injection of DC) and tissue sections evaluated by immunohistochemistry. In some experiments, injected DC were pre-labeled with CFSE to allow for discrimination of these therapeutic DC from endogenous, host DC. Tumors Figure  S1 ; Po0.01 versus the DC.null or DC.c5 treatment groups) and the CD11b þ CD11c þ myeloid DC subset (Supplementary Figure S2 ; Po0.01 versus the DC.null or DC.c5 treatment groups). On the basis of a parallel analysis of CD11c þ populations in the tumor-draining lymph nodes of treated mice, i.t. delivery of DC.IL32 also appeared to increase the trafficking of host (CD11c þ CFSE neg/dim ) DC to secondary lymphoid sites ( Figure 6) , consistent with the enhanced cross-priming of antitumor Tc1 in the periphery of these animals (Figure 4c ).
Tumors effectively treated with DC.IL32 were also characterized by an increased number of TUNEL þ CFSE neg (apoptotic) host cells (Figures 5c and d; Po0.01 versus control DC-treated tumors). Such apoptotic bodies are presumed to serve as the antigenic substrate for DC-mediated cross-priming of protective Tc1 responses fostered by i.t. IL-32 gene therapy. Despite reports that DC can directly mediate the apoptotic death of tumor cells, 26, 27 we did not observe that IL-32b cDNA engineering of DC resulted in their improved capacity to mediate tumoricidal function in vitro (Supplementary Figure S3 ).
Cells bearing the phenotypes of MDSCs, but not Treg, are reduced in DC.IL32-treated CMS4 tumors CD11b þ Gr1 þ MDSC and CD4 þ Foxp3 þ Treg are present in low levels in the circulation of healthy individuals, but have been reported to accumulate in the TME of cancer-bearing animals and patients, [28] [29] [30] where they antagonize the activation, function and survival of T effector cells. [28] [29] [30] To analyze whether DC.IL32-based therapy affects the levels of cells bearing the phenotype of MDSC and Treg in the TME, day 21 tumors were isolated from the various treatment cohorts and tissue sections analyzed by fluorescence microscopy. Although the number of tumor-infiltrating cells bearing the CD11b þ Gr1 þ phenotype was reduced in tumors from the DC.IL32-treated group (Figures 5a and b ; Po0.05 compared with tumors treated with either DC.null or DC.c5), levels of CD4 þ Foxp3 þ tumor-infiltrating lymphocyte were not found to differ significantly between the groups (Supplementary Figure S4) . Notably, the suppressive activity associated with Treg or MDSC isolated from CMS4 tumor lesions was not significantly affected by treatment with i.t.-delivered DC.IL32 ( Supplementary Figures S4 and S5) . Interleukin-32 gene therapy of cancer Y Qu et al DC.IL-32 mediates anti-angiogenic effects within the TME Given the increased propensity of DC.IL-32 to produce higher levels of IL-12p70 (when compared with control DC), a potent anti-angiogenic cytokine, 31, 32 we next determined whether i.t. delivery of DC.IL32 inhibits angiogenesis in the TME. Tumor sections were isolated from the various treatment groups 1 week after the second round of therapy (that is, day 21 post-tumor inoculation) and analyzed by immunofluorescence microscopy for blood vessels based on the expression of pericyte (that is, NG2) and vascular endothelial cell (that is, CD31) markers. We observed that treatment with DC.IL32 versus control DC.null or DC.c5, resulted in tumor blood vessels that were fewer in number, as well as, less dynamic in their branching patterns and smaller in their overall total surface area (Figures 5a and b ).
Discussion
We have shown that DC engineered to express the potent pro-inflammatory cytokine IL-32b defines a therapeutic modality when injected directly into murine tumor lesions. Therapeutic benefit is completely dependent on the development of treatment-induced CD8 þ T effector cells characterized by their capacity to elaborate IFN-g (that is, Tc1) in response to tumor-specific stimulation. Despite increased infiltration of CD4 þ T cells into the TME as a consequence of DC.IL32-based therapy, depletion of these T cells (or asialoGM1 þ NK cells) had little impact on the antitumor benefits associated with this treatment regimen. Overall, the ability of DC.IL32 to foster enhanced cross-priming of antitumor Tc1 responses is consistent with the changes invoked in these APC upon ectopic expression of IL-32b; for example, (i) increased production of IL-12p70, (ii) increased expression of MHC class I (but not class II) molecules, (iii) increased expression of co-stimulatory and integrin molecules (CD54, CD80, CD86) known to co-activate T cells and (iv) increased expression of CCR7, a secondary lymph node homing receptor required for the cross-priming of T-cell responses (by DC emigrating from tumors) in tissue-draining lymph nodes. Although the preferential upregulation of MHC I over MHC II molecule expression by DC.IL32 was suggestive of the potential influence of type-I IFNs in this model, 33 DC.IL32 failed to produce/ secrete detectable levels of these cytokines when monitored by commercial ELISA (data not shown).
Other factors that may promote enhanced MHC class I (over class II) expression include TNF-a. 34 Although IL-32b biologic activity has been defined based on its ability to promote TNF-a (along with IL-1, IL-6, IL-8 and CXCL2 among others; Kim et al. 6 ) from responder cell types, and IL-32 elaborated by DC.IL32 was able to activate TNF-a from the murine Raw264.7 macrophage cell line, it did not appear to promote autocrine TNF-a production from DC.IL32 themselves.
Our results suggesting the improved APC function of DC engineered to express transgene IL-32b contrast somewhat with a prior report by Netea et al. 35 who demonstrated that rIL-32g inhibited the rIL-4 þ rGM-CSF-driven differentiation of monocyte/macrophages into DC when added at high doses (that is, 30 ng ml -1 ) from the outset of cultures. In marked contrast, we have promoted IL-32b production from pre-differentiated DC. To determine the relevance of CD4 þ T cells, CD8 þ T cells or asGM1 þ natural killer (NK) cells in protection associated with i.t. delivery of DC.IL32, replicate cohorts of treated animals were also injected with specific depleting antibodies as described in Subjects and methods section. Tumor growth was monitored every 4 days. Data are reported as the mean±s.d. for five animals per group. **Po0.01 versus DC.null or DC.c5. In (b), Kaplan-Meier plots are provided for treatment with 1 Â 10 6 (n ¼ 15 mice) or 2.5 Â 10 6 (n ¼ 10 mice) DC.IL32 versus DC.null or DC.c5 treatment, respectively. Po0.05 for DC.IL32 (10 6 ) versus DC.c5 (10 6 ) or DC.null (10 6 ); Po0.001 for DC.IL32 (2.5 Â 10 6 ) versus DC.c5 (2.5 Â 10 6 ) or DC.null (2.5 Â 10 6 ), and Po0.01 for DC.IL32 (2.5 Â 10 6 ) versus DC.IL32 (10 6 ). In (c), to evaluate therapy-induced activation of antitumor Tc1 cells, on day 21 post-tumor inoculation, CD8 þ T cells were isolated from the spleens and tumor-draining lymph node (TDLN) of CMS4-bearing animals treated with DC.null, DC.c5 or DC.IL32. These effector cells were then analyzed for their ability to recognize relevant CMS4 tumor cells versus unrelated H-2 d MethA sarcoma cells based on interferon (IFN)-g secretion analyzed by enzyme-linked immunosorbent assay (ELISA) as described in Subjects and methods section. Data are reported as the mean±s.d. of triplicate determinations. **Po0.01 versus MethA.
Interleukin-32 gene therapy of cancer Y Qu et al
In this setting, one must appreciate that (i) the amount of IL-32b produced by DC.IL32 was only on the order of 1 ng ml -1 based on our ELISA results and (ii) IL-32b is the less biologically active splice product of IL-32g. 36 Under such lower dose conditions for IL-32b, any off-target (immuno)suppressive biology associated with IL-32b might well be avoided.
The most striking single change evoked by our IL-32 gene therapy was the (approximately 10-20-fold) enhanced presence of CD11b þ CD11c þ myeloid DC detected within the tumor lesion post-treatment with DC.IL32. These DC were of host origin and total DC numbers in the TME were not significantly impacted by the therapeutically injected DC population. Factors likely Figure 5 Intratumoral delivery of DC.IL32 promotes increased tumor infiltration by T cells and host dendritic cell (DC), reductions in tumor vascularity and myeloid-derived suppressor cell (MDSC) content, and the increased apoptotic death of tumor/stromal cells in the tumor microenvironment (TME). CMS4 tumor-bearing mice were treated as described in Figure 4 . On day 21 post-tumor inoculation, tumors were harvested and tissue sections analyzed for expression of CD4 þ T cells, CD8 þ T cells, CD11b þ Gr1 þ (MDSC) cells, and NG2 þ CD31 þ vascular structures by immunofluorescence microscopy as outlined in the Subjects and methods section. Representative images (a) and quantified numbers of events per high-power field (HPF; reported as mean±s.d. for 10 HPF per slide; b) are depicted. *Po0.05; **Po0.01 versus DC.null or DC.c5. CD31 vessel area is reported in microns 2 . For (c), BALB/c mice bearing established day 7 CMS4 tumors were treated with i.t. delivery of DC.IL32 or control DC pre-labeled with carboxyfluorescein succinimidyl ester (CFSE) (as described in Subjects and methods section). On day 21 post-tumor inoculation, tumors were harvested and tissue sections analyzed for: the presence of injected DC (CD11c þ CFSE þ ) versus host DC (CD11c þ CFSE neg ) and the presence of apoptotic DC (TUNEL þ CFSE þ ) versus tumor/tumor stromal cells (TUNEL þ CFSE neg ) by immunofluorescence microscopy as outlined in Subjects and methods section. **Po0.01 versus DC.null or DC.c5. Quantified numbers of events per high power field (HPF; reported as mean ± s.d. for 10 HPF per slide) are reported in (d). Similar data were obtained in three independent experiments performed.
Interleukin-32 gene therapy of cancer Y Qu et al to be involved in the therapeutic recruitment of host DC into the effectively treated, pro-inflammatory TME include the chemokines CCL2, CCL7 and/or CCL20. [37] [38] [39] [40] In prospective experiments, we will analyze the impact of injecting neutralizing Abs against these chemokines on recruitment of host CD11c þ DC into the TME and whether these antagonists ablate Tc1 cross-priming in vivo and therapeutic benefit. In preliminary MLR experiments, DC.IL32 did not promote differential T-cell proliferation when compared with control DC (DC.null or DC.c5), however, responder T cells harvested from DC.IL32 cultures were superior producers of IFN-g and inferior producers of IL-10. Hence, DC.IL32 likely provide differential developmental (that is, functional polarizing), rather than proliferative, signals to cross-primed type-1 CD8 þ T cells in the tumordraining lymph node. Interestingly, once Tc1 effector cells were activated systemically in treated mice, i.t.-delivered DC.IL32 also appeared to facilitate the recruitment of these T effector cells (approximately 2-3-fold) into tumor sites, likely via the enhanced production of CXCR3 ligand chemokines (such as, Mig/CXCL9) in the TME (Supplementary Figure S6 ). We are currently investigating the impact of antagonizing CXCR3 þ Tc1 infiltration into CMS4 tumors (using blocking anti-CXCR3 Abs) on the antitumor efficacy of DC.IL32-based therapy. Furthermore, IL-32b has been reported to upregulate endothelial cell expression of VCAM-1, 41 which may facilitate tumor infiltration by VLA-4 þ Tc1 cells in vivo. 24 Such therapyinduced vascular changes are likely of clinical significance since we observed a profound enrichment in tumor infiltration by CD8 þ T cells bearing a CXCR3 þ VLA-4 þ GrB þ phenotype after i.t. delivery of DC.IL32 ( Supplementary Figures S1 and S2) .
Somewhat surprisingly, DC.IL32-based therapy was effective despite promoting only a modest reduction (approximately 40%) in the number of cells bearing an MDSC phenotype, and no significant change in the number of cells bearing a CD4 þ Foxp3 þ Treg phenotype within the treated TME. This suggests that the dominant influence of DC.IL32-based therapy on type-1 CD8 þ T-cell-mediated immunity likely overrides the existing state of immune suppression and/or that the tumorresident MDSC/Treg have been rendered less effective in their inhibitory activities toward protective Tc1 cells. In support of the former contention, our preliminary analyses of flow-sorted CD11b þ Gr-1 þ MDSC and CD4 þ CD25 þ Treg cells from the TME of mice treated with DC.IL32 versus control DC indicate that these cell populations mediate a comparable level of immune suppressor activity (on a per-cell basis) regardless of the treatment cohort analyzed.
Although our studies suggest that transient expression of IL-32b by DC in the TME can be therapeutic, others have postulated that IL-32 expression (by tumor cells or infiltrating cells) in the context of chronic inflammation in the human TME may be involved in tumor progression and metastasis. 42, 43 Indeed, IL-32 can be expressed by human breast, gastric, lung and pancreatic carcinomas, in addition to glioblastoma multiforme. 42, 43 Although murine CMS4 tumor cells are deficient in IL-32 transcripts (Kim et al. 6 and reverse transcriptase-PCR data not shown), one is left to consider what determines the pro-/ antitumor impact of IL-32b in the TME? Most simplistically, this could be related to whether IL-32 expression is 'acute' versus 'chronic', with transient expression (as provided by DC.IL32) being associated with host protection. 6, 42, 44 Conceptually, by avoiding prolonged production of IL-32 in the TME, compensatory immunoregulatory changes may not be enforced, allowing for improved treatment benefit. This could underlie the reported link between IL-32 (that is, NK4) expression in the tumors of melanoma patients and superior therapy outcome after treatment with IL-2. 21 In addition to promoting improved type-1 antitumor immunity, i.t. delivery of DC.IL32 appears to alter the structure and activation status of blood vessels in the TME. We observed that tumors treated with DC.IL32 exhibited fewer and less dynamic blood vessel structures, which could relate to the potent anti-angiogenic activity of IL-12p70, 31, 32 that is produced at higher levels by DC.IL32 versus control DC. IL-32 has also been reported to inhibit COX-2 activity 45 thereby limiting vascular endothelial growth factor-supported neoangiogenesis. 46 Although we did not observe elevated production of TNF-a from DC after infection with Ad.IL-32b, this does not preclude secretion of this anti-angiogenic cytokine 47 from activated tumor/stromal cells in the TME of DC.IL32-treated mice, a possibility that we are now investigating. In conclusion, our results suggest pleiotropic protective effects resulting from i.t. delivery of DC.IL32 including the activation and recruitment of protective antitumor CD8 þ T cells into the TME. As IL-32-based therapy did not appear to profoundly deplete or inactivate MDSC or Treg in the TME, this suggests that combinational protocols employing agents that antagonize these suppressor cell populations (that is, sunitinib, anti-CTLA4 mAb, and so on 48, 49 ) have potential to yield an even greater degree of antitumor benefit.
